CoChat

IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN-γ Production

Open access

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

The antitumor effects of therapeutic mAbs may depend on immune effector cells that express FcRs for IgG. IL-12 is a cytokine that stimulates IFN-γ production from NK cells and T cells. We hypothesized that coadministration of IL-12 with a murine anti-HER2/neu mAb (4D5) would enhance the FcR-dependent immune mechanisms that contribute to its antitumor activity. Thrice-weekly therapy with IL-12 (1 μg) and 4D5 (1 mg/kg) significantly suppressed the growth of a murine colon adenocarcinoma that was engineered to express human HER2 (CT-26(HER2/neu)) in BALB/c mice compared with the result of therapy with IL-12, 4D5, or PBS alone. Combination therapy was associated with increased circulating levels of IFN-γ, monokine induced by IFN-γ, and RANTES. Experiments with IFN-γ-deficient mice demonstrated that this cytokine was necessary for the observed antitumor effects of therapy with IL-12 plus 4D5. Immune cell depletion experiments showed that NK cells (but not CD4(+) or CD8(+) T cells) mediated the antitumor effects of this treatment combination. Therapy of HER2/neu-positive tumors with trastuzumab plus IL-12 induced tumor necrosis but did not affect tumor proliferation, apoptosis, vascularity, or lymphocyte infiltration. In vitro experiments with CT-26(HER2/neu) tumor cells revealed that IFN-γ induced an intracellular signal but did not inhibit cellular proliferation or induce apoptosis. Taken together, these data suggest that tumor regression in response to trastuzumab plus IL-12 is mediated through NK cell IFN-γ production and provide a rationale for the coadministration of NK cell-activating cytokines with therapeutic mAbs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.1000328

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 100

Metadata

Authors
Jaime-Ramirez, A. C., Mundy-Bosse, B. L., Kondadasula, S., Jones, N. B., Roda, J. M., Mani, A., Parihar, R., Karpa, V., Papenfuss, T. L., LaPerle, K. M., Biller, E., Lehman, A., Ray Chaudhury, A., Jarjoura, D., Burry, R. W., & Carson, W. E.
Affiliations
  • Integrated Biomedical Sciences Graduate Program, College of Medicine, The Ohio State University , Columbus, OH 43210
  • The Ohio State University (US)
  • The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
  • Breast Cancer Center, Memorial Cancer Institute , Pembroke Pines, FL 33028
  • Cleveland Clinic (US)
  • Department of Pathology, The Ohio State University , Columbus, OH 43210
Corresponding author
Biller, Elizabeth
Venue
The Journal of Immunology
Published
2011-03
Volume
186
Issue
6
Pages
3401-3409
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W1924088703
Cited by
100
References
42
Citations by year
2026: 4 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 10 · 2019: 4 · 2018: 4 · 2017: 12 · 2016: 9 · 2015: 6 · 2014: 10 · 2013: 8 · 2012: 8
FWCI
4.47
Type
journal article
Language
en
Open access
Locations
  • The Journal of Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Ohio State University (CA16058, P30 CA16058)
  • National Institutes of Health (T32 CA90338-27, CA‐16058, CA95426)
  • National Cancer Institute (P01CA095426, K24CA093670, T32 CA90338-27, R21CA092286, P30CA016058)
  • National Institute of General Medical Sciences (T32GM068412)
  • National Center for Research Resources (UL1RR025755, K01RR022198)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
IL-12, trastuzumab, HER2/neu, natural killer cells, interferon-gamma, colon adenocarcinoma, RANTES, tumor regression, NK cell activation
MeSH terms
Trastuzumab, Adenocarcinoma, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Colonic Neoplasms, Cytotoxicity Tests, Immunologic, Female, Interferon-gamma, Killer Cells, Natural, Mice, Inbred BALB C, Random Allocation, Up-Regulation, Interleukin-12, Erb-b2 Receptor Tyrosine Kinases, Mice, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.